BIEL - Bioelectronics

This is a follow up on our previous analysis of Bioelectronics (BIEL). A study was released after market hours today comparing the effectiveness of the Actipatch vs. Tylenol extra strength. It was shown that the Actipatch was nearly 2x as effective in treating muscle pain amidst a 100 patient trial involving a placebo control. It remains the view of BHMP that upon FDA clearance of the company's 510k, that Bioelectronics will be in a prime position for a take over, or the selling of their technology. Companies such as Bayer or Johnson and Johnson would benefit greatly from absorbing such a company. This is a must buy and hold!

Target Buy Price - $.07-.10

Disclosure: Long Position